As GW842166x was found to be safe in phase II clinical trials for chronic pain [36], it is our hope that CB2 agonists can be repurposed for neuroprotection and the mitigation of anxiety and depression symptoms in PD. This evidence concerns the gene CNR2 and depressive symptom measurement.